This volume will focus on lymphoid malignancies. The editor has had a long career developing drugs in this specific disease, and thus will be able to leverage his network and familiarity with the space to produce the most timely work possible. Throughout history, lymphoma has been the disease where the majority of breakthrough developments have happened. From the origins of chemotherapy, to the implementation of novel small molecules and immunotherapies, there is no question that the development of Precision Cancer Therapies has had its greatest impact in these diseases, which has then been extrapolated to other forms of cancer. While the impact of this therapeutic ambition has not had the greatest impact in solid tumor malignancies, there are certainly many developments impacting how physicians are and will be managing these diseases with precision targeted drugs. Hence, future volumes of this series could be tailored to specific developments. As shown in the Table of Contents, each section on a specific biology or class of drugs will have an introductory chapter written by an authority in the field, exclusively focused on the biology, and its relevance to cancer biology. This approach will address the pressing need to help educate scientists, physicians, and the private sector about the broader context of the essential biology and extraordinary advances, an outcome I believe will redound on the fields ability to hasten the maturation of these assets, with the ultimate shared goal of helping all patients suffering from these challenging diseases. Authors of chapters that are the first of a section (that is focused more on the basic science aspects of the topic), are requested to focus exclusively on biology. In this chapter, the structure of which we defer to the primary author, a basic explanation of the underlying pathway and target should be reviewed in a comprehensive manner. It would be of value to provide some sense of the historical aspects as well. Subsequent subsections of the chapter should focus on how dysregulation of that pathway or target contribute to malignant transformation and cancer cell behavior. The case should be made on the rationale for targeting the biology, which should also cover the rationale for theoretical combinatorial approaches to achieve optimal target impairment. There should be no or very limited discussion of drugs, their pharmacology, or clinical data, as this will be covered by subsequent chapters. Chapters on specific therapeutics or therapeutic classes, should follow a basic structure, including: (i) Pharmacology of the drug/class, underscoring the drug presently available. (ii) Relevant Preclinical data, including monotherapy and combination therapy (iii) Pertinent clinical data. This can include summary tables of trials, and should also discuss toxicity and efficacy of the monotherapy. It should delineate between those drugs that are FDA approved, noting their indication, from those in development. (iv) Future Directions This can take any form you believe conveys the most exciting developments for the disease, and can focus on developments in biology or clinical management. A discussion of potential predictive biomarkers of response would be welcome. All chapters, irrespective of the Section, will have a boxed call-out on the first page of the chapter entitled ?Take Home Points?. This call out will highlight what you believe are the major unique points about the information in that Chapter in general. Each Take Home Point should be no more than one sentence and be brief. We suggest between 3 to 5 (no more) top-line points. In addition, above the formal References Cited section, we ask that you identify 2-3 publications, which can be original articles or reviews on the topic, entitled ?Must Reads?. These should be readings that allow the curious reader to go into more detail about principles important you believe are most important in that chapter.

• 关于产品：
• ● 正版保障：本网站隶属于中国国际图书贸易集团公司，确保所有图书都是100%正版。
• ● 环保纸张：进口图书大多使用的都是环保轻型张，颜色偏黄，重量比较轻。
• ● 毛边版：即书翻页的地方，故意做成了参差不齐的样子，一般为精装版，更具收藏价值。
• 
  关于退换货：
• 由于预订产品的特殊性，采购订单正式发订后，买方不得无故取消全部或部分产品的订购。
• 由于进口图书的特殊性，发生以下情况的，请直接拒收货物，由快递返回：
• ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全（例如：光盘等）
  并请在工作日通过电话400-008-1110联系我们。
• 签收后，如发生以下情况，请在签收后的5个工作日内联系客服办理退换货：
• ● 缺页/错页/错印/脱线
• 
  关于发货时间：
• 一般情况下：
• ●【现货】 下单后48小时内由北京（库房）发出快递。
• ●【预订】【预售】下单后国外发货，到货时间预计5-8周左右，店铺默认中通快递，如需顺丰快递邮费到付。
• ● 需要开具发票的客户，发货时间可能在上述基础上再延后1-2个工作日（紧急发票需求，请联系010-68433105/3213）；
• ● 如遇其他特殊原因，对发货时间有影响的，我们会第一时间在网站公告，敬请留意。
• 
  关于到货时间：
• 由于进口图书入境入库后，都是委托第三方快递发货，所以我们只能保证在规定时间内发出，但无法为您保证确切的到货时间。
• ● 主要城市一般2-4天
• ● 偏远地区一般4-7天
• 
  关于接听咨询电话的时间：
• 010-68433105/3213正常接听咨询电话的时间为：周一至周五上午8：30～下午5：00，周六、日及法定节假日休息，将无法接听来电，敬请谅解。
• 其它时间您也可以通过邮件联系我们：customer@readgo.cn,工作日会优先处理。
• 
  关于快递：
• ● 已付款订单：主要由中通、宅急送负责派送，订单进度查询请拨打010-68433105/3213。